ADPT vs DGX vs BLLN Stock Comparison

Adaptive Biotechnologies, Quest Diagnostics and BillionToOne Prices as of Nov 13, 2026 Peers: Industry group
DGX Quest Diagnostics Inc
$259.78 +11.3% 1M +38.5% 1Y
Market cap
$28.82B
P/E
25.5x
Revenue (TTM)
$11.84B
Div. yield
0.01%
Diagnostic Labs Healthcare
7 wins
BLLN BillionToOne, Inc.
$105.15 +7.4% 1M +17.4% 1Y
Market cap
$4.60B
P/E
100.1x
Revenue (TTM)
$436.87M
Div. yield
–
Diagnostic Labs Healthcare
3 wins

Head to Head

11 decided of 12

Quest Diagnostics leads on 7 of the 12 questions below (Quest Diagnostics 7, BillionToOne 3, Adaptive Biotechnologies 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionADPTDGXBLLNLeader
Larger companyMarket capitalisation $4.50B $28.82B $4.60B DGX
Cheaper on earningsLower P/E, profitable companies only -63.8x 25.5x 100.1x DGX
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 23.7x 114.3x DGX
Faster revenue growthRevenue growth, trailing twelve months +17.9% +9.1% +71.9% BLLN
More profitableNet margin, trailing twelve months -23.7% 9.5% 10.5% BLLN
Better return on capitalReturn on invested capital — 9.9% 6.9% DGX
Less leveragedLower net debt / EBITDA — 2.1x -9.1x BLLN
Higher dividend yieldTrailing dividend yield 0.00% 0.01% 0.00% –
Better 1-year returnPrice return, last 12 months +105.4% +38.5% +17.4% ADPT
Better 5-year returnAnnualised price return, 5 years -2.6%/yr +11.6%/yr — DGX
Less volatileAnnualised volatility, 1 year 67.6% 23.8% 91.9% DGX
Higher overall scoreMean of the five percentile scores vs peers 42/100 63/100 58/100 DGX

Percentile Scorecard

ADPTDGXBLLN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisADPTDGXBLLN
Valuation 12 #87 of 99 61 #39 of 99 22 #77 of 99
Growth 83 #16 of 89 41 #53 of 89 100 #1 of 89
Profitability 25 #69 of 92 82 #17 of 92 63 #35 of 92
Financial Health 70 #32 of 103 61 #41 of 103 96 #5 of 103
Shareholder Returns 21 #50 of 63 68 #21 of 63 7 #59 of 63
Overall 42 63 58
  • ADPT ranked among 103 companies in Healthcare Providers
  • DGX ranked among 103 companies in Healthcare Providers
  • BLLN ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodADPTDGXBLLNSPY
1 month +13.3%+11.3%+7.4% -2.0%
3 months +17.4%+10.9%+12.7% -2.8%
6 months +126.3%+39.2%+27.3% +2.0%
Year to date +78.8%+49.7%+28.5% +10.6%
1 year +105.4%+38.5%+17.4% +12.2%
3 years +610.0%+94.2%— +68.1%
3 years, per year +92.3%+24.8%— +18.9%
5 years -12.6%+73.2%— +61.4%
5 years, per year -2.6%+11.6%— +10.1%
10 years —+218.9%— +248.5%
10 years, per year —+12.3%— +13.3%

Risk

MeasureADPTDGXBLLNSPY
Volatility, 1Y 67.6%23.8%91.9% 13.6%
Downside volatility, 1Y 62.9%18.5%104.0% 13.9%
Beta vs S&P 500, 1Y 1.57-0.041.36 1.00
Return / volatility, 1Y 1.561.620.19 0.90
Max drawdown, 5Y -92.8%-30.3%-50.8% -25.4%
From 52-week high -4.0%0.0%-29.9% -3.2%
52-week high $30.26$259.78$149.97 $779.14
52-week low $12.41$173.49$64.03 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleADPTDGXBLLN
P/E now vs peer median -66.0xmedian 22.4x 25.3xmedian 22.4x 108.2xmedian 22.4x
P/S now vs peer median 15.7xmedian 1.3x 2.4xmedian 1.3x 11.5xmedian 1.3x
EV/EBITDA now vs peer median -132.7xmedian 14.2x 14.4xmedian 14.2x 87.4xmedian 14.2x
P/FCF now vs peer median -531.8xmedian 19.0x 20.8xmedian 19.0x 147.7xmedian 19.0x
P/B now vs peer median 25.5xmedian 2.6x 3.6xmedian 2.6x 8.8xmedian 2.6x
PEG now vs peer median -1.90median 0.84 1.73median 0.84 —median 0.84

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsADPTDGXBLLN
Revenue $298.01M $11.84B $436.87M
Gross profit $220.98M $3.92B $311.95M
Operating income -$48.21M $1.72B $44.69M
Net income -$70.73M $1.18B $49.39M
Free cash flow -$8.82M $1.38B $33.91M
R&D $83.18M – $66.47M
EPS (diluted) $-0.38 $10.08 $0.86
Cash & equivalents $75.62M $797.00M $561.51M
Total debt – $5.55B $89.00M
Shares (diluted) 186.88M 112.00M 53.73M
Enterprise value $3.41B $26.59B $2.46B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricADPTDGXBLLN
P/E -66.0x 25.3x 108.2x
P/FCF -531.8x 20.8x 147.7x
P/Operating cash flow -1,097x 14.6x 104.5x
P/S 15.7x 2.4x 11.5x
P/B 25.5x 3.6x 8.8x
P/Tangible book 25.6x 4.5x 8.8x
EV/EBITDA -132.7x 14.4x 87.4x
EV/EBIT -91.1x 19.3x 101.5x
EV/Revenue 14.7x 2.8x 10.4x
EV/FCF -498.0x 24.2x 133.8x
EV/Operating cash flow -1,027x 17.1x 94.7x
PEG (3Y EPS CAGR) -1.90 1.73 –

Growth

14 metrics
MetricADPTDGXBLLN
Revenue growth (1Y) 17.9% 9.1% 71.9%
Revenue CAGR (3Y) 18.4% 8.4% –
Gross profit growth (1Y) 21.7% 8.5% 88.4%
Gross profit CAGR (3Y) 27.3% 8.4% –
Operating income growth (1Y) 38.3% 12.5% 844.7%
Operating income CAGR (3Y) 37.3% 15.1% –
Net income growth (1Y) 11.1% 15.0% 593.9%
Net income CAGR (3Y) 28.8% 12.9% –
EPS growth (1Y) 22.7% 17.6% 193.7%
EPS CAGR (3Y) 34.7% 14.6% –
Operating cash flow growth (1Y) 92.9% 3.5% 794.7%
Operating cash flow CAGR (3Y) 70.1% 21.8% –
Free cash flow growth (1Y) 86.0% -1.3% 934.5%
Free cash flow CAGR (3Y) 62.8% 32.1% –

Profitability

14 metrics
MetricADPTDGXBLLN
Gross margin 74.2% 33.1% 71.4%
EBITDA margin -11.1% 19.5% 11.9%
Operating margin -16.2% 14.6% 10.2%
Pretax margin 5.1% 12.6% 11.4%
Net margin -23.7% 9.5% 10.5%
FCF margin -3.0% 11.6% 7.8%
Operating cash flow margin -1.4% 16.5% 11.0%
Return on equity -42.3% 15.0% 9.0%
Return on assets -10.7% 6.9% 6.6%
Return on invested capital – 9.9% 6.9%
Return on capital employed -8.6% 11.3% 6.5%
Asset turnover 0.5x 0.7x 0.6x
Cash conversion (OCF / net income) 0.1x 1.7x 1.0x
Stock comp / revenue 15.5% 0.7% 7.0%

Financial Health

11 metrics
MetricADPTDGXBLLN
Debt / assets – 32.2% 11.7%
Debt / equity – 0.7x 0.2x
Net debt / EBITDA – 2.1x -9.1x
Debt / FCF – 4.0x 2.6x
Liabilities / assets 73.1% 53.8% 25.5%
Equity / assets 26.9% 46.2% 74.5%
Interest coverage -5.3x 6.5x 1,655x
Current ratio 4.0x 1.7x 11.2x
Quick ratio 3.7x 1.4x 10.7x
Cash ratio 3.0x 0.4x 9.3x
Altman Z-score 3.45 3.82 16.82

Shareholder Returns

7 metrics
MetricADPTDGXBLLN
Dividend yield – 1.3% –
Net buyback yield -0.9% 1.1% -6.1%
Shareholder yield -0.9% 2.4% -6.1%
Payout ratio (earnings) – 31.3% –
Payout ratio (FCF) – 26.8% –
Dividend growth (1Y) – 6.3% –
Dividend CAGR (3Y) – 6.1% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusADPTDGXBLLN
Forward P/E – 23.7xFY2026 114.3xFY2026
EPS, next fiscal year $-0.42FY2026 $10.98FY2026 $0.92FY2026
EPS growth, next FY – +11.5%FY2026 +557.1%FY2026
EPS growth, the year after – +6.6% -2.2%
Revenue, next fiscal year $297.43MFY2026 $11.25BFY2026 $484.85MFY2026
Revenue growth, next FY +7.4%FY2026 +1.9%FY2026 +58.9%FY2026
Revenue growth, the year after +32.5% +7.7% +27.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersADPTDGXBLLN
Held by institutions 97.2% 94.4% 32.6%
Institutions holding 301 1,098 155
Change in shares held, QoQ +2.5% +2.7% +34.7%
Institutions buying 160 549 127
Institutions selling 87 342 13
Buyers to sellers 1.84 1.61 9.77

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ADPTDGXBLLN
ADPT 1.00 0.24 0.36
DGX 0.24 1.00 0.11
BLLN 0.36 0.11 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ADPT, DGX and BLLN?

Quest Diagnostics (DGX) is the largest by market capitalisation: Adaptive Biotechnologies (ADPT) $4.50B, Quest Diagnostics (DGX) $28.82B, BillionToOne (BLLN) $4.60B.

Which stock is cheaper, ADPT, DGX and BLLN?

Quest Diagnostics (DGX) trades on the lowest price-to-earnings ratio (Adaptive Biotechnologies (ADPT) -63.8x, Quest Diagnostics (DGX) 25.5x, BillionToOne (BLLN) 100.1x). On next year's consensus earnings, Quest Diagnostics (DGX) is cheapest (Quest Diagnostics (DGX) 23.7x, BillionToOne (BLLN) 114.3x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

BillionToOne (BLLN) grew revenue fastest over the trailing twelve months: Adaptive Biotechnologies (ADPT) +17.9%, Quest Diagnostics (DGX) +9.1%, BillionToOne (BLLN) +71.9%.

Which company is more profitable?

BillionToOne (BLLN) has the highest net margin (Adaptive Biotechnologies (ADPT) -23.7%, Quest Diagnostics (DGX) 9.5%, BillionToOne (BLLN) 10.5%). On return on invested capital, Quest Diagnostics (DGX) leads (Quest Diagnostics (DGX) 9.9%, BillionToOne (BLLN) 6.9%).

Which stock has performed better?

Over the past year Adaptive Biotechnologies (ADPT) returned the most: Adaptive Biotechnologies (ADPT) +105.4%, Quest Diagnostics (DGX) +38.5%, BillionToOne (BLLN) +17.4%. Over five years, Quest Diagnostics (DGX) compounded fastest (Adaptive Biotechnologies (ADPT) -2.6%/yr, Quest Diagnostics (DGX) +11.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Adaptive Biotechnologies (ADPT) 0.00%, Quest Diagnostics (DGX) 0.01%, BillionToOne (BLLN) 0.00%. Adaptive Biotechnologies (ADPT) and BillionToOne (BLLN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Quest Diagnostics (DGX) has been the steadiest (Adaptive Biotechnologies (ADPT) 67.6%, Quest Diagnostics (DGX) 23.8%, BillionToOne (BLLN) 91.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ADPT, DGX and BLLN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Quest Diagnostics (DGX) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.